See All Slides - tctmd.com

Slides

Presentation THT 2023

CCM® - Body of Evidence – What We Know and What We’re Learning

Presenter: Javed Butler

March 20, 2023

Presentation THT 2023

Treating the Failing Heart From Inside the LV Chamber: The AccuCinch Approach

Presenter: Ulrich Jorde

March 20, 2023

Presentation THT 2023

Conventional HF Management – Is There a Problem, and Whose Problem Is It?

Presenter: William Abraham

March 20, 2023

Presentation THT 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Presenter: Charles Dow

March 20, 2023

Presentation THT 2023

When and Why to Consider New Treatments for Our HF Patients

Presenter: Jacob Abraham

March 20, 2023

Presentation THT 2023

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Presenter: Song Li

March 20, 2023

Presentation THT 2023

Applications of Gene Therapy in Cardiomyopathies (TBD)

Presenter: Eric Adler

March 20, 2023

Presentation THT 2023

Biomarkers and Risk Stratification for Cardiogenic Shock

Presenter: Ajar Kochar

March 20, 2023

Presentation THT 2023

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Presenter: David Baran

March 20, 2023

Presentation THT 2023

Emerging Medical Pathways for Heart Failure Therapies

Presenter: Steven Marx

March 20, 2023

Advertisement

Slides

CCM® - Body of Evidence – What We Know and What We’re Learning

Treating the Failing Heart From Inside the LV Chamber: The AccuCinch Approach

Conventional HF Management – Is There a Problem, and Whose Problem Is It?

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

When and Why to Consider New Treatments for Our HF Patients

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Applications of Gene Therapy in Cardiomyopathies (TBD)

Biomarkers and Risk Stratification for Cardiogenic Shock

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Emerging Medical Pathways for Heart Failure Therapies

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content